MSD secures EU approval for its Zaire Ebola vaccine Ervebo
November 12, 2019Manufacturing and Production, Sales and Marketing Ebola, Ervebo, MSD, pharma
MSD has scored approval from the European Commission for Ervebo, the company’s Zaire Ebola vaccine, for the prevention of Ebola …
Novartis’ Kisqali approved for NHS Scotland in most common advanced breast cancer
November 12, 2019Manufacturing and Production, Sales and Marketing Cancer, Kisqali, NHS, Novartis, Scotland, breast cancer, pharma
NHS patients in Scotland will soon be able to access Novartis’ CDK4/6 inhibitor Kisqali (ribociclib) after the Scottish Medicines Consortium …
Lonza CEO to step down in 2020
November 12, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Lonza, appointment
It has been announced that Marc Funk, Chief Executive Officer at Lonza, is set to step down from the role …
Working Life Interview: Alison Muir, Oncology Product Strategy Director at Roche
November 11, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Roche, Working Life, feature, pharma
You studied biology at Liverpool John Moores University before heading straight to GSK in 1990 as a Sales Representative; was …
NHS to utilise first-ever cannabis-based therapies following NICE recommendation of two GW Pharma drugs
November 11, 2019Sales and Marketing Epidyolex, GW Pharma, NHS, Sativex, pharma
The NHS is authorised to use its first two cannabis-based medicines for routine use after NICE saw fit to recommend …
Roche’s risdiplam hits main goal in spinal muscular atrophy type 2 or 3
November 11, 2019Research and Development, Sales and Marketing Roche, pharma, risdiplam, spinal muscular atrophy
Roche has lifted the curtain on new data which shows that its investigational survival motor neuron-2 (SMN2) splicing modifier risdiplam …
Novartis reveals strong Phase 2b data for tropifexor in non-alcoholic steatohepatitis
November 11, 2019Research and Development, Sales and Marketing Novartis, nash, non-alcoholic steatohepatitis, pharma
The latest findings have been revealed from the final stage of Novartis’ Phase 2b evaluation of its non-bile acid FXR …
AnaptysBio’s etokimab fails in moderate-to-severe atopic dermatitis
November 11, 2019Sales and Marketing AnaptysBio; atopic dermatitis, pharma
AnaptysBio has announced disappointing new Phase 2b data for its anti-IL-33 candidate etokimab in the treatment of moderate-to-severe atopic dermatitis. …
Celgene and Acceleron’s Reblozyl secures FDA approval for anaemia in beta thalassaemia
November 11, 2019Sales and Marketing Acceleron, Celgene, Reblozyl, beta thalassaemia, pharma
The FDA has moved to authorise Celgene and Acceleron Pharma’s Reblozyl (luspatercept-aamt) in the treatment of anaemia associated with the …
Pfizer and Merck KGaA’s Bavencio falls short of primary endpoint in Phase 3 gastric cancer trial
November 8, 2019Medical Communications, Research and Development Bavencio, Merck KGaA, Pfizer, pharma
Pfizer and Merck KGaA’s EMD Serono have lifted the lid on new Phase 3 data for Bavencio (avelumab) in the …
Top Ten most popular articles on Pharmafile.com this week
November 8, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
In our rundown of the week’s most popular stories, President Donald Trump has named his first choice for the top …
Roche terminates Duchenne muscular dystrophy candidate due to poor clinical outlook
November 8, 2019Medical Communications, Research and Development Duchenne Muscular Dystrophy, Roche, pharma
Roche has revealed its decision to terminate further development of its anti-myostatin adnectin protein agent RG6206 after it became apparent …
AstraZeneca’s roxadustat boosts haemoglobin levels in two Phase 3 trials
November 8, 2019Medical Communications, Research and Development AstraZeneca, pharma, roxadustat
AstraZeneca’s hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) roxadustat has made a strong showing in the treatment of deficient haemoglobin (Hb) …
Takeda’s Ninlaro shows progression-free survival benefit in multiple myeloma
November 8, 2019Medical Communications, Research and Development Ninlaro, Takeda, multiple myeloma, pharma
Takeda has revealed strong new findings for Ninlaro (ixazomib), confirming that the therapy met its primary endpoint as a first-line …
J&J to supply 500,000 Ebola vaccines to fight DR Congo outbreak
November 7, 2019Manufacturing and Production, Research and Development, Sales and Marketing Ebola, Janssen, Johnson & Johnson, pharma
Johnson & Johnson has reached an agreement with the Government of the Democratic Republic of the Congo (DRC) to supply …
AstraZeneca reveals three-pronged “large-scale” R&D initiatives in China
November 7, 2019Manufacturing and Production, Research and Development, Sales and Marketing AstraZeneca, China
AstraZeneca has doubled down on its commitment to the Chinese region with the announcement of three “large-scale initiatives” in the …
Biogen scoops up eye and anti-TNF drug rights from Samsung Bioepis in $300m deal
November 7, 2019Sales and Marketing Biogen, Samsung Bioepis, pharma
Biogen has struck a new deal with Samsung Bioepis, it has emerged, picking up the commercialisation rights to a raft …
Endo President and CEO to retire, search for a successor begins
November 7, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Endo pharma, appointment
Endo International has announced its “CEO succession plan”, revealing that the company’s Chief Executive and President Paul V Campanelli has …
Strong Phase 3 showing for Takeda’s dengue vaccine, but concerns remain over consistent coverage
November 7, 2019Research and Development Takeda, dengue, pharma
Takeda has unveiled new data from its ongoing Phase 3 trial investigating the efficacy of its vaccine candidate TAK-003 in …
Aveo backs off on tivozanib approval after FDA calls for more conclusive data
November 6, 2019Research and Development, Sales and Marketing Aveo Oncology, FDA, pharma
Aveo Oncology has hit another hurdle in its quest for approval of its vascular endothelial growth factor receptor tyrosine kinase …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
